Chronic widespread pain and fibromyalgia syndrome : life-course risk markers in young people by Tan, Aidan C. (R20305) et al.
Review Article
Chronic Widespread Pain and Fibromyalgia Syndrome:
Life-Course Risk Markers in Young People
Aidan C. Tan ,1 Tiina Jaaniste,2,3 and David Champion 2,3
1Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
2Department of Pain and Palliative Care, Sydney Children’s Hospital, Sydney, New South Wales, Australia
3School of Women’s and Children’s Health, University of New South Wales, Sydney, New South Wales, Australia
Correspondence should be addressed to David Champion; dchamp@bigpond.net.au
Received 17 February 2019; Accepted 12 March 2019; Published 5 May 2019
Guest Editor: Emilia Matera
Copyright © 2019 Aidan C. Tan et al. 'is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Although the life-course concept of risk markers as potential etiological influences is well established in epidemiology, it has not
featured in academic publications or clinical practice in the context of chronic widespread pain (CWP) and fibromyalgia
syndrome (FMS). Studies of risk markers are required considerations for evaluation of patients and for research because there is
no single cause, pathological feature, laboratory finding, or biomarker for CWP or FMS. 'e early-life risk markers identified by
extensive literature review with best evidence for potential causal influence on the development and progression of CWP and FMS
include genetic factors, premature birth, female sex, early childhood adversity, cognitive and psychosocial influences, impaired
sleep, primary pain disorders, multiregional pain, physical trauma, infectious illness, obesity and inactivity, hypermobility of
joints, iron deficiency, and small-fiber polyneuropathy. 'e case history illustrates the potential etiological influence of multiple
risk markers offset by personal resilience.
1. Introduction
'e causal influences on persistent multisite, multiregional,
or widespread pain disorders in a young person are often
perplexing to physicians and patients. Despite evidence of
abnormal nervous system findings, neurophysiological
signatures, low-grade systemic inflammation and neuro-
inflammation, and biochemical alterations in plasma and
muscle proteins [1–3], there are no sensitive and specific
laboratory findings, biomarkers, or pathological features
for chronic widespread pain (CWP) and fibromyalgia
syndrome (FMS). 'us, in the absence of a single cause, the
etiological focus shifts towards risk markers, defined by
Burt [4], as attributes or exposures that are associated with
an increased probability of disease, but do not necessarily
constitute a causal factor. 'e conservative term risk
marker is preferred to risk factor, association, or comor-
bidity in this context. Few risk markers for CWP and FMS
have been empirically demonstrated to be causal, and there
is uncertainty in the literature about whether a risk factor
should be a causal link in the etiological chain or may be
peripherally associated with an outcome. 'ere is also
uncertainty in the literature about what strength of asso-
ciation is needed for an attribute or exposure to be a risk
factor for an outcome and how directly it needs to be
associated with the outcome.
In this review, the risk markers of CWP and FMS in a
young person were considered in a clinical vignette and from
a life-course perspective. 'e life-course approach has
demonstrated the influence of early-life events across var-
ious health outcomes, including pain [5, 6]. Identifying risk
markers enables a shared understanding of the biopsy-
chosocial antecedents of CWP and FMS and guides early
identification, risk prediction, and targeted prevention.
Ultimately, the hope is that a life trajectory towards chronic
pain can be prevented or interrupted.
In young children, the most common pain disorders
without overt disease or trauma—termed idiopathic, non-
specific, functional, or primary—are growing pains, re-
current abdominal pain, and headaches [7]. By age 14, the
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most common pain disorders are headache, abdominal pain,
and back pain [8], and children with one pain disorder not
infrequently experience multiple other pain disorders [9–
15]. 'ese childhood pain disorders are antecedents of
chronic pain in adolescence and adulthood, with long-term
persistence, particularly of recurrent abdominal pain and
low back pain [16]. Predictors of the transition from acute to
persistent musculoskeletal pain in children and adolescents
in a prospective study are female sex and poorer conditioned
pain modulation, while higher depressive symptoms are
associated with higher pain-related disability and poorer
quality of life [17]. 'ese features, especially collectively, are
likely antecedents to CWP.
CWP is defined as pain in upper and lower and right and
left quadrants, for more than threemonths duration [18].
'e prevalence of widespread pain in school-aged children is
7–15% [19, 20]. 'e prevalence of chronic multisite pain in
female and male adolescents aged 13–19 is 11.4% and 3.8%,
respectively [21], and in young adults aged 22 is 10.9% [22].
A twin study by Kato et al. found the overall prevalence of
CWP to be 4.1%.
In CWP meeting criteria for FMS, cognitive, affective,
and sensory features emerge, with evidence of abnormal
brain networks, altered biology of pain processing, and
disturbance of neurobiological function. FMS is defined,
especially for epidemiological studies, by the presence of
CWP accompanied by chronic fatigue, disturbed sleep, and a
spectrum of symptoms associated with nociceptive ampli-
fication of neural signaling within the central nervous system
[14, 23–27].'ere are no validated criteria or evidence-based
consensus guidelines for the diagnosis of juvenile FMS
[28–30]. Ting et al. [31] concluded that the 2010/2011
American College of Rheumatology fibromyalgia criteria
[25] had diagnostic applicability in adolescent females;
however, there are no published studies of juvenile FMS
which have applied the 2016 revisions to the 2010/2011
fibromyalgia criteria [29].
'e onset of juvenile FMS is typically in late childhood
and early adolescence. 'e prevalence of juvenile FMS in
children and adolescents is estimated at 1.3%, but up to
3.5% to 6.2% for those aged between 15 and 19, and is
substantially higher in females than males [32]. Of ado-
lescents with juvenile-onset FMS, more than 80% dem-
onstrate persistence of pain, physical impairment,
emotional impairment, and other symptoms into early
adulthood, and half later meet the full criteria for adult
FMS [33].
CWP and FMS cases, as defined, lie on a spectrum from
primary pain disorders [34] where the recently introduced
term nociplastic [35] may be applied, to secondary dis-
orders where a substantial causal risk factor or causal in-
fluence is evident, such as injuries in a motor vehicle
accident. In some cases, termed primary FMS, there are no
obvious peripheral nociceptive generators or life-course
risk markers. In such cases, genetic factors and impaired
endogenous pain modulation might apply, and primary
pain disorders may precede or accompany the FMS. In
other cases, risk markers are prominent, as in the clinical
vignette.
1.1. Clinical Vignette. At the time of presentation, the
patient, a 25-year-old woman employed in a clerical
position, reported a history of persistent pains in wide
distribution including hands, feet, ankles, knees, hip re-
gions, back, and neck, as well as headaches. She could be
“sore” all day, though was typically better in the morning
and worse in the evening. 'e associated symptoms in-
cluded her feet “going to sleep,” coldness and bluish-white
discoloration of fingers and toes, fine tremor of hands,
minor subjective swelling of hands, minor sleep impair-
ment, waking unrefreshed, self-reported mild cognitive
difficulties, and low energy. Her self-assessed mood was
“okay,” but she acknowledged “a lot of anxiety” with a
tendency to panic reactions. 'e pain had gradually
evolved from childhood and had intensified during ad-
olescence. No obvious disease had been identified, and
extensive medical consultations and investigations for
inflammatory rheumatic disorders had been negative or
inconclusive.
'e principal findings on examination weremild obesity,
fine hand tremor, moderate hypermobility of joints (meeting
Beighton score and arthralgia criteria), and widespread deep
tenderness (low-pressure pain threshold). On cutaneous
somatosensory testing at a time of relative quiescence of
symptoms, responses to cutaneous stimuli, including static
and repetitive punctate pressure, were normal. Responses to
repetitive deep pressure stimuli at the pain threshold, in wide
distribution, demonstrated facilitated temporal summation
of pain intensity, minor persistence of after-sensations, but
no radiation, interpreted as inferring mild generalized
central sensitization. 'e 2016 revised diagnostic criteria for
FMS [25–27] were met.
Past medical and family history revealed a remarkable
life-course of potential vulnerability factors for chronic pain
disorders:
(i) Family history of depression in both parents,
significant anxiety in her father, and migraine in
her maternal grandfather.
(ii) Born six weeks premature.
(iii) Childhood adversity through parental disharmony
and subsequent divorce at 8 years of age.
(iv) Anxiety and depression from childhood. At the
time of presentation, anxiety was more prominent
than depression, with occasional panic episodes.
(v) Primary (functional) childhood pain disorders,
including growing pains and headaches in early
childhood, and a diagnosis of common migraine
several years later.
(vi) Iron deficiency, though it was unknown whether
this dated from infancy.
(vii) Trauma resulting in fracture of radius and ulna at
8 years of age and fracture of an ankle a year or two
later without major sequelae.
(viii) Motor vehicle accident with cervical whiplash
injury at 9 years of age.
(ix) Hypermobility of joints.
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(x) Severe Streptococcal throat infection at 16 years of
age, followed by chronic fatigue from which she
had not recovered. 'is coincided with the exac-
erbation and chronicity of her pain.
In view of the array of risk markers combining to create a
high-risk phenotype for chronic pain disorders, consider-
ation was given as to why the expression of this young
woman’s chronic pain disorder was relatively mild. It was
apparent that she possessed protective factors including
emotional intelligence, social support, good employment,
and regular exercise.
2. Methods
A literature review was performed by searching the elec-
tronic bibliographic databases MEDLINE (via Ovid) and
EMBASE (via Ovid), using strategies widely used in sys-
tematic reviews, from their inception until September 2017.
Search terminology was identified through the controlled
vocabulary thesauruses Medical Subject Headings (MeSH)
and Emtree. To identify the most appropriate MeSH, the
MeSH tree structure was used, and the subject headings
“chronic pain,” “fibromyalgia,” “risk factors,” “child,” “ad-
olescent,” and “young adult” were selected. 'is method was
replicated for Emtree, and identical subject headings were
selected. 'e search was limited to English language pub-
lications, but no other filters were applied. Subject headings
were combined with the Boolean operators “OR” and
“AND” to find their intersection (Table 1).
Citations were screened by title and abstract for rele-
vance to risk markers for CWP or FMS in children, ado-
lescents, or young adults. 'e full-text publications of
relevant abstracts were attained, and the reference lists of
relevant studies were manually reviewed. Our primary focus
was family, genetic, and pediatric association studies. Studies
of risk markers for CWP or FMS in adults were added when
it was apparent that many risk markers provide inferences
and hypotheses applicable to young adults and adolescents.
Studies of associations and comorbidities likely to be sec-
ondary to CWP or FMS were excluded, including restless
legs syndrome, low bonemineral density, and cardiovascular
disease aggravation. Trauma and infection were included
because, like most risk markers, they typically have only
contributory causal influences.
'e literature search identified 475 articles. After ex-
cluding 93 duplicates, citation screening of the remaining
382 articles excluded 276 articles based on irrelevance. 'e
full-text publications of the remaining 106 articles were
obtained, reviewed, and qualitatively synthesized. To grade
the strength of the research evidence, we adapted the
modified grading of recommendations assessment, devel-
opment, and evaluation (GRADE) framework for a narrative
synthesis by Huguet et al. [36].
3. Results
Table 2 presents the studies of familial and genetic influences
on CWP and FMS. Until recently, FMS diagnosis required
physical examination, and thus, large population studies
were unavailable. Stronger evidence for familial and genetic
risk markers for CWP has come from population-based twin
studies.
Table 3 lists the published risk markers for CWP and
FMS determined in pediatric studies. 'ese risk markers
reflect underlying neurobiological processes which are in-
completely understood. Overall, the graded strength of re-
search evidence, determined using the four quality
categories defined by the original GRADE framework [65],
high, moderate, low, and very low quality, was greater for
risk markers for CWP than FMS because of the earlier
availability of questionnaire surveys.
Table 4 displays the modifiable and nonmodifiable risk
markers for CWP and FMS from adult studies. Generally,
the data were applicable to young adults and adolescents.
Again, stronger evidence for risk markers applied to CWP.
3.1. Familial and Genetic Vulnerability. In a population-
based twin study [39], Vehof et al. demonstrated that
chronic pain syndromes, including CWP, irritable bowel
syndrome, chronic pelvic pain, and spinal pain, [40] shared
an underlying genetic factor with an estimated heritability of
66%. Vehof and Williams [93] suggested that the once
evolutionary advantage of high pain sensitivity may have
turned into a genetic predisposition to the neurobiological
underpinnings of chronic pain. Parental CWP was shown to
increase the risk of CWP in adult offspring, particularly if
both parents had CWP, and offspring were obese [41].
Table 1: Search strategy.
# Searches Results
MEDLINE
1 Exp chronic pain/ 9400
2 Exp fibromyalgia/ 7898
3 1 or 2 16903
4 Exp risk factors/ 730540
5 Exp child/ 1810174
6 Exp adolescent/ 1905521
7 Exp young adult/ 646590
8 5 or 6 or 7 3134864
9 3 and 4 and 8 240
10 Limit 9 to English language 230
EMBASE
1 Exp chronic pain/ 48537
2 Exp fibromyalgia/ 17126
3 1 or 2 62529
4 Exp risk factor/ 837344
5 Child/ 1681331
6 Adolescent/ 1453055
7 Exp young adult/ 200970
8 5 or 6 or 7 2611330
9 3 and 4 and 8 255
10 Limit 9 to English language 245





Final number of articles 106
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Table 2: Familial and genetic influences for chronic widespread pain and fibromyalgia.
Pain context Type of study Population orclinic
Number of
participants Multivariate analysis Reference Overall quality
∗
CWP Twin study Population 44,897 No Kato et al. [37] +++
CWP Twin study Population 926 Yes Burri et al. [38] ++++
CWP Twin study Population 8564 Yes Vehof et al. [39] +++
CWP Twin study Population 2256 Yes Malkin et al. [40] +++
CWP Prospective population cohort Population 6589 Yes Zadro et al. [41] ++++
CWP Review N/A N/A N/A Kerr and Burri [42] N/A
FMS Family study Clinic 805 Yes Arnold et al. [43] ++
FMS Review N/A N/A N/A Park et al. [44] N/A
∗Overall quality: + , very low; ++ , low; +++ , moderate; ++++ , high.
Table 3: Risk markers for chronic widespread pain and fibromyalgia in pediatric samples.













CWP Prospectivepopulation cohort Population 7,571 Yes
Jones et al.
[19, 45, 46] +++
CWP Prospectivepopulation cohort Population 7,470 No
Jones et al.
[19, 45, 46] +++
CWP Prospectivepopulation cohort Population 1,440 Yes
Jones et al.
[19, 45, 46] +++
FMS Case-control Clinic 36 No Olivieri et al.[47] +
FMS Case-control Clinic 117 No Bohn et al. [48] +





FMS Case-controlretrospective Clinic 75 Yes Hellou et al. [50] ++
Psychosocial factors




population cohort Population 2,509 No Davies et al. [52] +++
(iii) Peer
relationships Yes FMS Case-control Clinic 110 No
Kashikar-Zuck
et al. [53] +
(iv) Stress, anxiety,
and depression
Yes CWP Prospectivepopulation cohort Population 7,571 Yes
Jones et al.
[19, 45, 46] +++
CWP Prospectivepopulation cohort Population 7,470 Yes
Jones et al.
[19, 45, 46] +++
CWP Prospectivepopulation cohort Population 1,440 Yes
Jones et al.
[19, 45, 46] +++
CWP Prospectivepopulation cohort Population 2,650 Yes
Nicholl et al.
[54] +++
CWP Cross-sectional Population 7,070 No Skrove et al. [21] ++
FMS Population survey Population 3,006 Yes Wolfe et al. [55] ++
FMS Case series Clinic 76 No Kashikar-Zucket al. [56] +
FMS Prospectivecohort Clinic 121 Yes
Cunningham
et al. [57] +++
(v) Temperament Possibly FMS Case-control Clinic 48 No Conte et al. [58] +
(vi) Posttraumatic
stress disorder Possibly CWP
Cross-sectional




status (low) Possibly CWP
Prospective
population cohort Population 9,377 Yes
Macfarlane et al.
[60] +++
Sleep problems Yes FMS Case series Clinic 30 No Tayag-Kier et al.[61] +
Physical trauma No CWP Prospectivepopulation cohort Population 7,571 Yes Jones et al. [45] +++
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Table 3: Continued.











Yes CWP Prospectivepopulation cohort Population 7,470 No
Jones et al.
[19, 46] +++




joints No FMS Cross-sectional Clinic 131 No Ting et al. [62] +
Chronic fatigue No CWP Population birthcohort Population 3214 Yes Norris et al. [63] ++++
Small-fiber
polyneuropathy No FMS Case series Clinic 41 No
Oaklander and
Klein [64] +
∗Overall quality: + , very low; ++ , low; +++ , moderate; ++++ , high.
Table 4: Risk markers for chronic widespread pain and fibromyalgia in adult samples.










No CWP Prospectivepopulation cohort Population 28,367 Yes
Mundal et al.
[66] +++
CWP Systematic review N/A N/A N/A Mansfield et al.[67] N/A
CWP Review N/A N/A N/A Mogil [68] N/A






Yes CWP Prospectivepopulation cohort Population 28,367 Yes
Mundal et al.
[66] +++












[38, 71, 72] ++++
(ii) Emotional
intelligence (low) Possibly CWP Twin survey Population 3,266 Yes Burri et al. [71] ++++
(iii) Posttraumatic
stress disorder
Possibly CWP Prospectivepopulation cohort Population 1,312 Yes
Raphael et al.
[73] +++
FMS Cross-sectional Clinic 395 No Häuser et al.[74] ++
(iv) Socioeconomic
status (low) Possibly CWP
Prospective












population cohort Population 8572 Yes Pang et al. [76] +++
Preterm birth No CWP Prospectivepopulation cohort Population 8572 Yes
Littlejohn et al.
[77] +++
Sleep problems Yes CWP
Prospective
population cohort Population 3,171 Yes Gupta et al. [70] +++
FMS Review N/A N/A N/A Choy [78] N/A
Physical trauma No CWP Prospectivecohort Clinic 948 No Hu et al. [79] ++
Functional/primary
pain disorders
Yes CWP Prospectivecohort Clinic 423 Yes Viniol et al. [80] ++
CWP Retrospectivecohort Clinic 512 Yes
Kindler et al.
[81] ++
FMS Case-control Clinic 625 Yes Warren et al.[82] ++
FMS Cross-sectional Clinic 1,123 Yes de Tommasoet al. [83] ++
FMS Controlled trial Clinic 86 No Giamberardinoet al. [84] +
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Reviewing eight twin studies on CWP, six molecular genetic
studies on CWP, and one epigenetic study, the findings by
Kerr and Burri [42] suggested that genetic and unique
environmental factors contributed to CWP. Various can-
didate genes, such as serotonin-related pathway genes, were
found to be associated with CWP.
Most studies which have documented psychosocial de-
terminants of CWP have been unable to exclude genetic
confounding, given the strong heritability of some risk
markers, notably depression and anxiety. Burri et al. [71]
used a discordant monozygotic-twin approach to overcome
the traditional limitations of conventional epidemiology by
separating environmental influences from genetic con-
founders to provide clues on the direction of causality. 'e
results, supported by another twin study [38], demonstrated
that the covariance between CWP and depression and
anxiety was due to a common, highly heritable, and latent
trait.
Research on genetic predisposition to FMS has revealed
associations between genetic factors and FMS, including
specific gene polymorphisms involved in serotonergic, do-
paminergic, and catecholaminergic pathways [44, 94]. FMS
coaggregated in families with reduced pressure pain
thresholds and major mood disorder [43].
3.2. Female Sex. CWP and FMS demonstrated female pre-
dominance [95], with juvenile FMS affecting females four
times more than males [29]. 'is female predominance is
incompletely understood, but likely involves genetic, psy-
chological, behavioral (including reporting behavior), and
neurobiological factors [68].
3.3. Early-Life Adversity. Early-life adversity was a risk
marker for developing adult CWP and FMS. Epidemio-
logical studies of the 1958 British Birth Cohort Study
demonstrated that multiple somatic symptoms at age 7 were
independently associated with CWP at age 45 [19, 45, 46].
Moderate associations included headaches, abdominal pain,
and periodic vomiting [46], and significant associations
included hospitalization following a road traffic accident,
residence in institutional care, maternal death, familial fi-
nancial hardship, and persistent behavioral problems
[45, 76, 96]. Whilst the association between preterm birth
and very low birthweight and adult CWPwas not statistically
significant [77], extremely premature babies who underwent
repeated procedures after birth demonstrated sustained
changes in sensory processing by age 11 [97].
Other studies have demonstrated that painful infant
experiences and childhood maltreatment were associated
with adult FMS. 'ese associations included preterm birth,
perinatal exposure to substances of abuse, maternal depri-
vation, growing up with a depressed parent, psychological
trauma, physical or verbal abuse from parents, and physical
or sexual abuse by an adult [47–49]. Abuse in childhood was
associated with a 97% increased risk of painful somatic
syndromes in adulthood, including FMS [98].
Early-life adversity may increase vulnerability to CWP
and FMS by excessively activating stress responses during a
critical period and altering normal development, stress re-
activity, and nociceptive function through hyperalgesic
priming. 'e pain itself is a stressor and, as it evolves, may
generate a positive feedback loop to increase anxiety levels
and impact stress regulation.
3.4. Cognitive and Psychosocial Factors. Early childhood
cognitive and psychosocial problems are risk markers for
CWP. In children, the independent risk markers for
widespread pain were adverse behavioral and emotional
factors, somatic pain symptoms, older age, female sex, de-
pression, and regional back and neck pain symptoms
[19, 20]. In adolescents, CWP was associated with anxiety,
Table 4: Continued.











Yes CWP Prospectivepopulation cohort Population 28,367 Yes
Mundal et al.
[66] +++
CWP Prospectivepopulation cohort Population 1,553 Yes
Magnusson
et al. [85] +++
FMS Review N/A N/A N/A Ursini et al. [86] N/A
Iron deficiency Yes FMS Case-control Clinic 92 No Ortancil et al.[87] +
Hemochromatosis Yes FMS Cross-sectional Clinic 295 No Mohammadet al. [88] +




Possibly FMS Review N/A N/A N/A Buskila et al.[90] N/A
FMS Review N/A N/A N/A Häuser et al.[91] N/A
FMS Prospectivecohort controlled Population 1,244 Yes Chen et al. [92] +++
∗Overall quality: + , very low; ++ , low; +++ , moderate; ++++ , high.
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depression, and conduct or attentional problems [21]. For
young people aged 10–18, higher widespread pain scores
were associated with poorer mental and physical health-
related quality of life and greater functional impairment.
Whilst this relationship was explained by psychosocial
distress, including somatization features, health-seeking
behavior, insecure attachment style, and poor sleep, the
causal direction has not been established [52, 54, 70, 99].
Resilience factors, including high self-esteem, seldom feeling
lonely, and high scores for family cohesion or social con-
fidence, were associated with a lower prevalence, and
markedly attenuated the association between psychiatric
symptoms and CWP [21].
In adults, prospective studies from the 1958 British Birth
Cohort Study demonstrated that low socioeconomic status
at age 7 was associated with CWP at age 45 [60] and
appeared to be explained by psychological factors [52].
Additionally, low intellectual and emotional intelligence,
low social class, low educational attainment, high body mass
index, and psychological distress in childhood were in-
dependent predictors of CWP in adulthood [51].
In later life, risk markers for CWP included the psy-
chological factors of anxiety and depression, lifestyle factors
of smoking and obesity, and other factors such as dys-
function of the hypothalamic-pituitary-adrenal axis [66, 89].
Posttraumatic stress disorder was strongly associated with
CWP and FMS [59, 73, 74], likely mediated in part by the
known enhanced influence on central sensitization and
common antecedent traumatic experiences.
Juvenile FMS was associated with temperamental in-
stability, low mood, depression and anxiety, family disorder,
social isolation, higher pain and emotional sensitivity, and
lower psychological adjustment [53, 58]. Psychiatric disor-
ders, notably anxiety, were prevalent in juvenile and early
adulthood FMS and were associated with greater physical
impairment, poorer functioning, and lower health-related
quality of life [56, 57]. 'e lifetime prevalence of psychiatric
comorbidity, notably depression, anxiety, and bipolar dis-
order, with FMS may suggest a shared underlying patho-
physiological link.
3.5. Sleep Problems. Poor self-reported sleep quality was a
risk marker for CWP and FMS [78]. Whilst children with
juvenile FMS demonstrated abnormal α-rhythms (sugges-
tive of wakefulness during nonrapid eye movement sleep),
periodic limb movements, prolonged sleep latency, short-
ened total sleep time, decreased sleep efficiency, and in-
creased wakefulness during sleep, the causal relationship is
unclear [61]. Sleep deprivation impairs descending pain-
inhibition pathways and can cause myalgia, tenderness, and
fatigue, suggesting that sleep dysfunctionmight not only be a
consequence of pain but also pathogenetic [78].
3.6. Physical Trauma. 'e 1958 British Birth Cohort Study
demonstrated the association between childhood trauma
and CWP [45]. One of the major childhood risk markers for
adult CWP was hospitalization following a road traffic
accident, though this may be influenced by the associated
psychological sequalae.
Of individuals who presented to an emergency de-
partment after motor vehicle collision, 11% developed CWP
[79]. 'is is consistent with evidence that spinal pain not
uncommonly evolves into CWP. In adult females with FMS,
childhood trauma had a clinically important association
with loss of functionality and comorbid depression [100].
3.7. Functional/Primary Pain Disorders and Multiregional
PainDisorders. CWP and FMS often evolved over time from
multiregional pain disorders. Headaches and abdominal
pain in children were associated with a doubling of the risk
of developing widespread body pain in the ensuing year [19].
Children aged 7 with abdominal pain, headaches, migraine,
or vomiting attacks had an increased risk of CWP at age 45
[46].
Adults with back or neck pain were particularly at risk of
CWP, and the same risk was likely to apply to children and
adolescents [15]. 'e incidence of CWP in adults with
chronic low back pain was 23.8% [80], and the rate of de-
veloping CWP within 5-6 years in adults with regional back
or neck pain was 22.6% [81]. 'e risk markers associated
with the transition to CWP were moderate or severe pain
intensity, female sex, long duration of back pain, high rate of
psychosomatic symptoms, history of abuse, family history of
CWP, severe interference with general activities, having one
or more central sensitivity syndromes, and using more pain
management strategies. Additionally, functional somatic
syndromes were risk markers for CWP, specifically chronic
fatigue, irritable bowel syndrome, and chronic pelvic pain
[82], and for FMS, specifically migraine [83, 84].
3.8. Hypermobility of Joints. In adolescents with juvenile
FMS, 48% have been clinically assessed as having hyper-
mobility of joints [62]. Hypermobility of joints was asso-
ciated with enhanced physiological pain sensitivity.
3.9. Obesity. Obesity and low physical activity have been
epidemiologically associated with chronic pain, including
CWP [66, 86] and FMS [86, 101]; however, studies in ad-
olescents have only reported associations between obesity
and the prevalence and severity of knee pain and chronic
regional pain [102]. Obesity can be considered an aggra-
vating comorbid condition affecting condition severity,
quality of life, fatigue, and physical dysfunction. Poor
physical fitness was a key covariate in increasing the risk of
both widespread pain and obesity [85]. Other potential
causal influences of obesity on CWP and FMS included
physical inactivity, sleep disturbance, depression, endocrine
dysfunction, lower pressure pain thresholds, and in-
flammatory and immune effects [103–105].
3.10. Rheumatic Conditions. 'e 2016 revised fibromyalgia
criteria permitted a diagnosis of FMS in association with any
medical illness, including inflammatory musculoskeletal
disorders. 'ere has been a tendency for CWP and a deep
Pain Research and Management 7
hyperalgesic state occurring in 10–30% of patients with
primary rheumatic diseases, including rheumatoid arthritis
and systemic lupus erythematosus, to be termed secondary
or comorbid FMS. However, this is best referred to by the
primary diagnosis and the additional interpretation of
widespread deep secondary allodynia or low-pressure pain
threshold reflecting central sensitization [95]. It is ac-
knowledged that the inflammatory rheumatic condition
might not be the sole source of nociceptive input or source of
central somatosensory dysfunction.
3.11. Iron Deficiency. Iron deficiency, especially in early life,
may be a risk marker for CWP. In a twin family study, we
observed an independent association between iron de-
ficiency and chronic pediatric pain [106]. A serum ferritin
level <50 ng/ml was associated with a 6.5-fold increased risk
for FMS in females [87]. Paradoxically, FMS has also been
associated with hemochromatosis [88].
3.12. Infectious Illness. Various infections have been linked
to FMS. Epstein–Barr and parvovirus infections, brucellosis,
and Lyme disease were often cited [90, 91], but any infectious
illness characterized by prolonged bed rest and persistent
fatigue might be a causal influence. Postinfection chronic
fatigue syndrome is probably a more appropriate diagnostic
term, especially in those in whom fatigue is dominant over
pain. Microglial activation may underpin postinfectious
contributions to CWP.
3.13.Small-FiberPolyneuropathy. Small-fiber polyneuropathy,
alongside chronic neuroinflammation, was associated with
CWP and FMS, with claims of causation. In patients with
widespread pain beginning before age 21, small-fiber pol-
yneuropathy was “definite” in 59% and “probable” in 17%
[64].
4. Discussion
'e literature leaves little doubt that some children and
adolescents have increased vulnerability to developing CWP
and FMS. 'e risk markers for CWP and FMS suggest a
complex etiological structure which shares risk markers with
those identified in other chronic pain disorders. Evidence for
potential mechanisms underpinning these risk markers is
emerging at molecular, cellular, and network levels [107].
Alterations in the structure, wiring, function, and neuro-
chemistry of various brain networks, particularly the
reward-motivation network and the endogenous pain
modulation system, might be involved in conferring vul-
nerability to pain conditions. Epigenetic modulation, lead-
ing to changes to neuronal and molecular processes, is one
way in which genetics and adverse priming events, including
prior injury or stressful environmental influences, may in-
crease risk. In FMS, neuropathological changes include
regional changes in grey matter volume, decreased func-
tional connectivity in the descending pain-modulating
system, and an increased activity in the pain matrix
related to central sensitization. Whether measurable alter-
ations in brain function precede or follow the onset of
chronic pain, they might lead to a vicious cycle in which
vulnerability leads to nonresilience to additional factors
arising from the chronic pain state. It is likely that biological,
psychological, social, and contextual risk markers interact to
predispose, initiate, maintain, and exacerbate CWP and FMS
[72].
A model of life-course influences on the development of
chronic pain was published by Dominick and Blythe [108].
'e model by Von Baeyer and Champion [12] was de-
veloped to illustrate factors in the development of multiple
functional (or primary) pain disorders, but could appro-
priately be applied to life-course risk markers in the de-
velopment of CWP and FMS in young people. It is likely that
biological, psychological, social, and contextual variables
interact to influence the predisposition, triggering, and
aggravation of CWP and FMS. To integrate current
knowledge, theory, and hypotheses, we propose a biopsy-
chosocial model of risk markers for chronic widespread pain
and fibromyalgia syndrome in young people (Figure 1). For a
more specific model for FMS, see Häuser et al. [91], and for
juvenile FMS, see Kashikar-Zuck and Ting [28].
'e majority of the risk markers have at least some
potential for modification. 'ere is less or no prospect of
favorable modification of sex, temperament, intelligence,
hypermobility of joints, small-fiber polyneuropathy, phys-
ical trauma, and chronic fatigue.
Although this review was based on extensive literature
review and evaluation of the strength of research evidence,
the review was limited by the possible selectivity of searches
and citations, and publication bias underestimating negative
results.
5. Conclusion
'e strongest evidence for risk markers as potential causal
influences on CWP and FMS (Tables 2–4) came from
prospective cohort studies, notably birth cohorts, and ge-
netic studies, mainly twin analyses. Genetic influences were
prominent but not always overt, including shared genes
between widespread pain and depression, widespread pain
and spinal pain, and functional/primary pain syndromes.
Low emotional intelligence merits more attention, given the
strength of evidence. 'e social risk markers, including
childhood adversity and low socioeconomic status, were
prominent across numerous studies and were at least partly
related to stress, anxiety, and depression.
'e case presented illustrates how a history of risk
markers over the life-course can provide insight into why a
young person might acquire CWP fulfilling criteria for FMS.
Her risk markers were family history, premature birth,
childhood adversity, hypermobility of joints, mild obesity,
anxiety and depression, multiple primary or functional pain
disorders, physical trauma, iron deficiency, and infectious
illness with chronic fatigue. Such a cumulative burden ev-
idently determined the onset by adolescence of her CWP,
but typically the diagnostic categorization was made several
years after the symptoms had become well established,
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notwithstanding consultations and intensive investigations.
e taking of an earlier insightful history of the risk markers
could have identi	ed reversible factors leading to a more
favorable trajectory and might have worked to mutual ad-
vantage for the patient and physician. It is likely that per-
sonal resilience can limit the severity of CWP and FMS and
warrants further research with an aim to developing in-
terventions designed to increase personal resilience.
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